Crizanlizumab-tmca (Adakveo)





PATIENT INFORMATION	Referral Status	: □ New R	eferral 🗆 Upo	dated Orde	er 🔲 Order Renewal	
Patient Name:		DOB:		atient Pho		
Patient Address:	Patient Email:					
Allergies:		□ NKDA	Weight (lbs/kg	g):	Height (in/cm):	
Sex: □ M / □ F Date of Last Infusion:	Next Due Date: Preferred Location:					
DIAGNOSIS (<i>Please provide ICD-10 code in space</i>) Sickle Cell Disease:	provided)					
THERAPY ADMINISTRATION & DOSING Induction: Administer crizanlizumab-tmca (Adakveo) kg x 5mg/kg = mg IV over 30mins on week 0 and week 2 Maintenance: Administer crizanlizumab-tmca (Adakveo) kg x 5mg/kg = mg IV over 30mins every 4 weeks ADDITIONAL ORDERS		LABORATORY ORDERS □ Other: PRE-MEDICATION ORDERS □ Tylenol □ 500mg / □ 650mg PO □ Loratadine 10mg PO □ Pepcid 20mg □ PO / □ IVP □ Benadryl □ 25mg / □ 50mg □ PO / □ IVP □ Solumedrol □ 40mg / □ 125mg IVP □ Other: NURSING □ Drug may cause interference with automated platelet counts, use citrate tubes or run test as soon as possible □ Provide nursing care per Nursing Procedure, including Hypersensitivity Reaction Management Protocol and post-procedure observation				
PROVIDER INFORMATION		Drot	Formed Contact E	maile		
Preferred Contact Name:		Preferred Contact Email:				
Ordering Provider: Referring Practice Name:	٩a	Provider NPI: Phone: Fax:				
Practice Address:	Pr Ci		State:	ΓdX.	Zip Code:	
					•	
REQUIRED DOCUMENTATION CHECKLIST (A Required Documentation: Patient demos, copy of fro treatment failures or contraindications						
Provider Name (print) Order valid for one year unless otherwise indicated. IV solutions/dilue	vider Signatur		manufacturer's insti		rate	